Belite Bio to Participate in the Leerink Partners Global Healthcare Conference
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company developing treatments for degenerative retinal diseases, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference.
The event will take place in Miami, FL from March 10-12, 2025. The company's executive management team will host a fireside chat on Monday, March 10, 2025, at 3:00 pm ET.
Investors and interested parties can access the webcast through the 'Events' section on Belite Bio's investor relations website. The presentation recording will remain available for 90 days after the event.
Belite Bio (NASDAQ: BLTE), una compagnia biofarmaceutica in fase clinica che sviluppa trattamenti per malattie retiniche degenerative, ha annunciato la sua partecipazione alla prossima Conferenza Globale sulla Sanità di Leerink Partners.
L'evento si svolgerà a Miami, FL dal 10 al 12 marzo 2025. Il team di gestione esecutiva dell'azienda ospiterà una discussione informale lunedì 10 marzo 2025, alle 15:00 ET.
Investitori e parti interessate possono accedere alla trasmissione in diretta attraverso la sezione 'Eventi' sul sito web delle relazioni con gli investitori di Belite Bio. La registrazione della presentazione rimarrà disponibile per 90 giorni dopo l'evento.
Belite Bio (NASDAQ: BLTE), una empresa biofarmacéutica en etapa clínica que desarrolla tratamientos para enfermedades retinianas degenerativas, ha anunciado su participación en la próxima Conferencia Global de Salud de Leerink Partners.
El evento se llevará a cabo en Miami, FL del 10 al 12 de marzo de 2025. El equipo de gestión ejecutiva de la empresa realizará un charla informal el lunes 10 de marzo de 2025, a las 3:00 pm ET.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección 'Eventos' en el sitio web de relaciones con inversores de Belite Bio. La grabación de la presentación estará disponible durante 90 días después del evento.
Belite Bio (NASDAQ: BLTE)는 퇴행성 망막 질환 치료제를 개발하는 임상 단계의 생명공학 회사로, 다가오는 Leerink Partners 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다.
이 행사는 2025년 3월 10일부터 12일까지 마이애미, FL에서 개최됩니다. 회사의 경영진 팀은 2025년 3월 10일 월요일 오후 3시(ET)에 파이어사이드 챗을 진행할 예정입니다.
투자자 및 관심 있는 분들은 Belite Bio의 투자자 관계 웹사이트의 '이벤트' 섹션을 통해 웹캐스트에 접근할 수 있습니다. 발표 녹화는 행사 후 90일 동안 이용 가능합니다.
Belite Bio (NASDAQ: BLTE), une entreprise biopharmaceutique en phase clinique développant des traitements pour les maladies dégénératives de la rétine, a annoncé sa participation à la prochaine Conférence Mondiale sur la Santé de Leerink Partners.
L'événement se déroulera à Miami, FL du 10 au 12 mars 2025. L'équipe de direction de l'entreprise animera une discussion informelle le lundi 10 mars 2025, à 15h00 ET.
Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct via la section 'Événements' du site web des relations investisseurs de Belite Bio. L'enregistrement de la présentation sera disponible pendant 90 jours après l'événement.
Belite Bio (NASDAQ: BLTE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das Behandlungen für degenerative Netzhauterkrankungen entwickelt, hat seine Teilnahme an der bevorstehenden Leerink Partners Global Healthcare Conference angekündigt.
Die Veranstaltung findet vom 10. bis 12. März 2025 in Miami, FL statt. Das Führungsteam des Unternehmens wird am Montag, dem 10. März 2025, um 15:00 Uhr ET ein Fireside Chat veranstalten.
Investoren und Interessierte können über den Bereich 'Veranstaltungen' auf der Investor-Relations-Website von Belite Bio auf den Webcast zugreifen. Die Aufzeichnung der Präsentation bleibt 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the Leerink Partners Global Healthcare Conference being held on March 10-12, 2025, in Miami, FL. The Company will host a fireside chat on Monday, March 10, 2025, at 3:00 pm ET.
A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replay will be archived for 90 days following the presentation date.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases that have significant unmet medical needs such as Stargardt disease type 1, or STGD1 and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, and is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at http://www.belitebio.com.
Media Relations Contact:
Jennifer Wu
ir@belitebio.com
Investor Relations Contact:
Julie Fallon
belite@argotpartners.com
FAQ
When is Belite Bio (BLTE) presenting at the Leerink Partners Conference 2025?
How can investors watch Belite Bio's (BLTE) Leerink Conference presentation?
How long will Belite Bio's (BLTE) Leerink Conference presentation be available for replay?
What is Belite Bio's (BLTE) main focus in drug development?
